Original Article
Author Details : Ranjana Hawaldar*, Sadhna Sodani, Varsha Sodani, R K Sodani
Volume : 8, Issue : 2, Year : 2021
Article Page : 75-78
Abstract
Introduction: India began administration of COVID-19 vaccines on 16 January 2021. Reliable quantification of the antibody response to SARS-CoV-2 vaccination is highly relevant for identifying possible vaccine efficiency and estimating the time of protection. Healthcare Professionals were the first group of beneficiaries of this vaccine.Objectives: we aimed to evaluate the neutralizing [anti-RBD] antibody responses induced by COVID-19 vaccines after first and booster dose in healthcare professionalsMaterials and Methods: 69 healthcare professionals [HCPs] Were enrolled for the evaluation study. The COVISHILED vaccine developed by AstraZeneca, University of Oxford and manufactured and distributed in India by the Serum Institute of India was administered to all the participants. All participants were evaluated to detect levels neutralizing IgG antibodies on three occasions:,first pre vaccination level, second on approximately 27th day and third on 68th day from baselining & first vaccine dose to assess change in levels of neutralizing IgG antibodies post vaccinationResults: On approximately 27 day from first vaccine dose, 45 out of 51 participants in investigational cohort were sero-converted for anti-RBD antibodies. Out of 6 participants that were yet to sero-convert 5 demonstrated increased level of neutralizing [anti-RBD] antibodies but did not cross the reactivity threshold to confirm presence of neutralizing [anti-RBD] antibodies.On approximately 68 day from second vaccine dose, 49 out of 51 participants in investigational cohort were sero-converted for anti-RBD antibodies. 4 additional participants sero-converted post booster dose .96.0% produced neutralizing [anti-RBD] antibodies post vaccination. 2 participants continued to remain non-reactive.Conclusion: This is the first data of serological responses to COVID-19 vaccines in IBD patients with detailed analysis of antibodies RBD/spike proteins represented amongst HCPs from central India. Study also demonstrates that the level of neutralizing antibodies produced may vary due to several contributing factors and hence periodic monitoring of neutralizing antibodies before and post vaccination can help evaluate adaptive immune response induced by specific individual in response to vaccine administered.Keywords : Vaccination, Covishield, Immunity, S1RBD, HCPs.
How to cite : Hawaldar R, Sodani S, Sodani V, Sodani R K, Study of neutralizing [anti-RBD] antibody responses induced by COVID-19 vaccines in healthcare professionals in a diagnostic centre of Central India. J Community Health Manag 2021;8(2):75-78
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Previous Article
Next Article
We recommend
SARS-CoV-2 IgG antibody seroprevalence in the general population of Indore City: A population-based cross-sectional study Ranjana Hawaldar et al., The Journal of Community Health Management, 2021
Efficacy of COVID-19 vaccine in elderly Indian population with Vitamin D and Iron deficiency Deepika Gujjarlapudi et al., IP Journal of Nutrition, Metabolism and Health Science, 2022
Seroprevalence of COVID-19 infection among healthcare professionals in Central India using SARS-CoV-2 antibody test Ranjana Hawaldar et al., The Journal of Community Health Management, 2020
Evaluation of antibodies against SARS-CoV-2 and their patterns of response in health care workers and general population at a tertiary care Centre Srihita M et al., IP Indian Journal of Immunology and Respiratory Medicine, 2021
Immunological response in health care workers post COVID-19 vaccination Kanwardeep Singh et al., Annals of Geriatric Education and Medical Sciences, 2023
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study Katherine Adams et al., The BMJ, 2022
Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO Elisabeth Mahase, The BMJ, 2022
Vaccination Against Covid-19: Recommendations for Candidates and Transplant Recipients Raquel Silveira Bello Stucchi et al., Brazilian Journal of Transplantation - BJT, 2022
Anti-HBs prevalence and assessment of the response to serological Hepatitis B vaccine in patients eligible for liver transplantation at Hospital Santa Isabel of Blumenau/Santa Catarina Marcelo Augusto Scheidemantel Nogara et al., Brazilian Journal of Transplantation - BJT, 2014
Updated TCM Treatment in Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 9th Edition) and Its Guidance on Preventing and Treating SARS-CoV-2 Omicron Variant Infection FANG Bangjiang QI Wensheng YANG Zhixu YE Yong LI Xucheng ZHOU Shuang LIU Li et al., Journal of Shaanxi University of Chinese Medicine, 2022
For More Info Article
Comments